Experience Always Wins the Day: Measure of Warfarin Anticoagulation Efficiency in the Internal Medicine Clinic

Thi Hoang Lan Nguyen, Nathalye Belzile, Madeleine Durand, Josee Leroux-Stewart, Stephanie Thebeau, Oceane Landon-Cardinal, Robert Wistaff, Paul-Van Nguyen, Maxime Lamarre-Cliche, Christoph Kolan, Mikhael Laskine


Background: In the real-life setting of a specialized anticoagulation clinic we think that the patient’s INRs fall within the therapeutical range most of the time. Our study aimed to assess the time spent by patients treated by Warfarin with INR between 2.0 and 3.0, as well the time spent between 1.5 and 3.5. We chose this new range (1.5 - 3.5) because we think that it is safe and completely acceptable in real-life situation, and requires only minor adjustments to return to treatment goal of 2.0 to 3.0.

Methods: A single-center, retrospective observational study was conducted at Hotel-Dieu Hospital, between June 2010 and December 2011. Inclusion criteria were (1) to be treated for venous thromboembolic event with Warfarin, and (2) to have at least 3 INR measurements during the study period.

Results: The median duration of follow-up was 281 days with a total number of INR values of 2,553. Median proportion of time at target INR (2.0 - 3.0) was 68.9%. This proportion increased to 98.7% between 1.5 and 3.5. There was a single recurrent thrombosis event, 6 minor bleeding episodes and 10 major bleeding episodes. The majority of major bleeding episodes were caused by gastrointestinal bleeding.

Conclusions: We demonstrated that patients followed at a specialized anticoagulation clinic spend on average 68.9% of their time within the therapeutical range of INR and 98.7% of their time within very safe and effective INR values. Indeed, Warfarin is still a valuable treatment for thromboembolic event and a very competitive drug.

doi: http://dx.doi.org/10.4021/jh100e

Keywords (3-8)*

Warfarin; Anticoagulation therapy; Thromboembolic event; INR; Therapeutic range

Full Text: HTML PDF
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe



Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board



Company Profile

Editorial Office

Misconduct and Retraction


Company Registration

Contact Us

Abstracting and Indexing



Instructions to Authors


Declaration of Helsinki

Contact Publisher

Submission Checklist


Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy


Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians


Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal


Journal of Hematology, quarterly, ISSN 1927-1212 (print), 1927-1220 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thejh.org    editorial contact: editor@thejh.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.